NCT07083531 Bone Loss, Physical Function and Frailty in Older Women With Sickle Cell Trait Sickle Cell Trait
| NCT ID | NCT07083531 |
| Status | Recruiting |
| Phase | — |
| Sponsor | UConn Health |
| Condition | Sickle Cell Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 50 participants |
| Start Date | 2022-08-23 |
| Primary Completion | 2025-08-23 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 50 participants in total. It began in 2022-08-23 with a primary completion date of 2025-08-23.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a cross-sectional, clinical research study comparing postmenopausal women of African Descent (AD) with different hemoglobin genotypes: normal and sickle cell trait (SCT). This research study has two purposes. The first purpose is to determine whether having SCT is a risk factor for the development of bone thinning in older women. The second purpose is to investigate whether women with SCT have reduced muscle function and increased frailty compared to women without SCT. The investigators estimate enrolling 50 female volunteers who are at least 50 years old and have not had a menstrual period for at least 12 consecutive months. Volunteers need not know whether they have SCT as this will be evaluated as part of the study.
Eligibility Criteria
Inclusion Criteria: * Female of African Decent. * Age 50 years or older. * Lack of menstrual period for at least 12 consecutive months Exclusion Criteria: * Taking medications known to influence bone metabolism (e.g., glucocorticoids, hormonal therapy, cancer or chemotherapy meds, anti-resorptive medications or anabolic therapies). * Known metabolic bone disorder (e.g., uncontrolled thyroid disease, hyperparathyroidism, Vitamin D deficiency) * Taking an investigational drug * Documented sickle cell disease
Contact & Investigator
Biree Andemariam, MD
PRINCIPAL INVESTIGATOR
UConn Health
Frequently Asked Questions
Who can join the NCT07083531 clinical trial?
This trial is open to female participants only, aged 50 Years or older, studying Sickle Cell Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07083531 currently recruiting?
Yes, NCT07083531 is actively recruiting participants. Contact the research team at zgreen@uchc.edu for enrollment information.
Where is the NCT07083531 trial being conducted?
This trial is being conducted at Farmington, United States.
Who is sponsoring the NCT07083531 clinical trial?
NCT07083531 is sponsored by UConn Health. The principal investigator is Biree Andemariam, MD at UConn Health. The trial plans to enroll 50 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.